{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T01:27:37Z","timestamp":1769045257058,"version":"3.49.0"},"reference-count":66,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:00:00Z","timestamp":1689120000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Cancer Research UK","award":["C2215\/A21421"],"award-info":[{"award-number":["C2215\/A21421"]}]},{"name":"Cancer Research UK","award":["13034"],"award-info":[{"award-number":["13034"]}]},{"name":"Cancer Research UK","award":["BH152495"],"award-info":[{"award-number":["BH152495"]}]},{"name":"Cancer Research UK","award":["BH152694"],"award-info":[{"award-number":["BH152694"]}]},{"DOI":"10.13039\/501100007903","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["C2215\/A21421"],"award-info":[{"award-number":["C2215\/A21421"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["13034"],"award-info":[{"award-number":["13034"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["BH152495"],"award-info":[{"award-number":["BH152495"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007903","name":"Blood Cancer UK","doi-asserted-by":"publisher","award":["BH152694"],"award-info":[{"award-number":["BH152694"]}],"id":[{"id":"10.13039\/501100007903","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010089","name":"JGW Paterson Foundation","doi-asserted-by":"publisher","award":["C2215\/A21421"],"award-info":[{"award-number":["C2215\/A21421"]}],"id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010089","name":"JGW Paterson Foundation","doi-asserted-by":"publisher","award":["13034"],"award-info":[{"award-number":["13034"]}],"id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010089","name":"JGW Paterson Foundation","doi-asserted-by":"publisher","award":["BH152495"],"award-info":[{"award-number":["BH152495"]}],"id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010089","name":"JGW Paterson Foundation","doi-asserted-by":"publisher","award":["BH152694"],"award-info":[{"award-number":["BH152694"]}],"id":[{"id":"10.13039\/100010089","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Newcastle Healthcare Charity","award":["C2215\/A21421"],"award-info":[{"award-number":["C2215\/A21421"]}]},{"name":"Newcastle Healthcare Charity","award":["13034"],"award-info":[{"award-number":["13034"]}]},{"name":"Newcastle Healthcare Charity","award":["BH152495"],"award-info":[{"award-number":["BH152495"]}]},{"name":"Newcastle Healthcare Charity","award":["BH152694"],"award-info":[{"award-number":["BH152694"]}]},{"name":"Turkish Ministry of National Education","award":["C2215\/A21421"],"award-info":[{"award-number":["C2215\/A21421"]}]},{"name":"Turkish Ministry of National Education","award":["13034"],"award-info":[{"award-number":["13034"]}]},{"name":"Turkish Ministry of National Education","award":["BH152495"],"award-info":[{"award-number":["BH152495"]}]},{"name":"Turkish Ministry of National Education","award":["BH152694"],"award-info":[{"award-number":["BH152694"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Chronic lymphocytic leukemia (CLL) is a genetically and clinically heterogeneous malignancy affecting older individuals. There are a number of current treatment options for CLL, including monoclonal antibodies, targeted drugs, chemotherapy, and different combinations of these. However, for those patients who are intrinsically treatment resistant, or relapse following initial responses, novel targeted therapies are still needed. Targeting the mouse double-minute-2 human homolog (MDM2), a primary negative regulator of p53, is an appealing therapeutic strategy for non-genotoxic reactivation of p53, since the TP53 gene is in its wild-type state at diagnosis in approximately 90% of patients. Mutated SF3B1 and TP53 are both associated with more aggressive disease, resistance to therapies and poorer overall survival for CLL. In this study, we performed a screen for SF3B1 and TP53 mutations and tested RG7388 (idasanutlin), a second-generation MDM2 inhibitor, in a cohort of CLL primary patient samples. SF3B1 mutations were detected in 24 of 195 cases (12.3%) and found associated with poor overall survival (hazard ratio [HR] 2.12, p = 0.032) and high CD38 expression (median CD38 (%) 32 vs. 5; p = 0.0087). The novel striking finding of this study was an independent link between SF3B1 mutational status and poor response to RG7388. Overall, SF3B1 mutations in CLL patient samples were associated with resistance to treatment with RG7388 ex vivo, and patients with the wild type for both SF3B1 and TP53 are more likely to benefit from treatment with MDM2 inhibitors.<\/jats:p>","DOI":"10.3390\/ijms241411335","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T00:50:41Z","timestamp":1689123041000},"page":"11335","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["SF3B1 Mutations Are Associated with Resistance to Non-Genotoxic MDM2 Inhibition in Chronic Lymphocytic Leukemia"],"prefix":"10.3390","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9400-0938","authenticated-orcid":false,"given":"Erhan","family":"Aptullahoglu","sequence":"first","affiliation":[{"name":"Medical Faculty, Newcastle University Cancer Centre, Newcastle upon Tyne NE2 4AD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan P.","family":"Wallis","sequence":"additional","affiliation":[{"name":"Department of Haematology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helen","family":"Marr","sequence":"additional","affiliation":[{"name":"Department of Haematology, Freeman Hospital, Newcastle upon Tyne NHS Foundation Trust, Newcastle upon Tyne NE7 7DN, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Marshall","sequence":"additional","affiliation":[{"name":"Department of Haematology, City Hospitals Sunderland NHS Trust, Sunderland SR4 7TP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Bown","sequence":"additional","affiliation":[{"name":"Northern Genetics Service, Institute of Genetic Medicine, Newcastle upon Tyne NE1 4EP, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4762-094X","authenticated-orcid":false,"given":"Elaine","family":"Willmore","sequence":"additional","affiliation":[{"name":"Medical Faculty, Newcastle University Cancer Centre, Newcastle upon Tyne NE2 4AD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1878-8583","authenticated-orcid":false,"given":"John","family":"Lunec","sequence":"additional","affiliation":[{"name":"Medical Faculty, Newcastle University Cancer Centre, Newcastle upon Tyne NE2 4AD, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1002\/ajh.26367","article-title":"Chronic lymphocytic leukemia: 2022 update on diagnostic and therapeutic procedures","volume":"96","author":"Hallek","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/nature15395","article-title":"Mutations driving CLL and their evolution in progression and relapse","volume":"526","author":"Landau","year":"2015","journal-title":"Nature"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1200\/JCO.20.00979","article-title":"Prediction of Outcome in Patients With Chronic Lymphocytic Leukemia Treated With Ibrutinib: Development and Validation of a Four-Factor Prognostic Model","volume":"39","author":"Ahn","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1182\/blood.2018884940","article-title":"Acalabrutinib monotherapy in patients with relapsed\/refractory chronic lymphocytic leukemia: Updated phase 2 results","volume":"135","author":"Byrd","year":"2020","journal-title":"Blood"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in Patients with CLL and Coexisting Conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"3115","DOI":"10.1182\/blood-2002-03-0972","article-title":"Phase 2 study of a combined immunochemotherapy using rituximab and fludarabine in patients with chronic lymphocytic leukemia","volume":"100","author":"Schulz","year":"2002","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"a000893","DOI":"10.1101\/cshperspect.a000893","article-title":"p53 Research: The Past Thirty Years and the Next Thirty Years","volume":"2","author":"Lane","year":"2010","journal-title":"Cold Spring Harb. Perspect. Biol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"4473","DOI":"10.1200\/JCO.2009.27.8762","article-title":"TP53 Mutation and Survival in Chronic Lymphocytic Leukemia","volume":"28","author":"Zenz","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1182\/blood-2005-12-5148","article-title":"Mdm2 inhibitor Nutlin-3a induces p53-mediated apoptosis by transcription-dependent and transcription-independent mechanisms and may overcome Atm-mediated resistance to fludarabine in chronic lymphocytic leukemia","volume":"108","author":"Kojima","year":"2006","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/bjc.2017.433","article-title":"Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma","volume":"118","author":"Wu","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"40115","DOI":"10.18632\/oncotarget.9499","article-title":"Pre-clinical efficacy and synergistic potential of the MDM2-p53 antagonists, Nutlin-3 and RG7388, as single agents and in combined treatment with cisplatin in ovarian cancer","volume":"7","author":"Zanjirband","year":"2016","journal-title":"Oncotarget"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Chamberlain, V., Drew, Y., and Lunec, J. (2021). Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53WT Uterine Leiomyosarcoma. Cancers, 14.","DOI":"10.3390\/cancers14010014"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.3324\/haematol.2018.206631","article-title":"Non-genotoxic MDM2 inhibition selectively induces a pro-apoptotic p53 gene signature in chronic lymphocytic leukemia cells","volume":"104","author":"Ciardullo","year":"2019","journal-title":"Haematologica"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1182\/blood.2022016362","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: A non-randomized, open-label phase 1b trial","volume":"141","author":"Daver","year":"2022","journal-title":"Blood"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1101\/gad.10.2.233","article-title":"Evidence that sequence-independent binding of highly conserved U2 snRNP proteins upstream of the branch site is required for assembly of spliceosomal complex A","volume":"10","author":"Gozani","year":"1996","journal-title":"Genes Dev."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1146\/annurev.bi.65.070196.002055","article-title":"The structure and function of proteins involved in mammalian pre-mRNA splicing","volume":"65","author":"Kramer","year":"1996","journal-title":"Annu. Rev. Biochem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"SomaticSF3B1Mutation in Myelodysplasia with Ring Sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/ng.2674","article-title":"Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3","volume":"45","author":"Martin","year":"2013","journal-title":"Nat. Genet."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1084\/jem.20110921","article-title":"Analysis of the chronic lymphocytic leukemia coding genome: Role of NOTCH1 mutational activation","volume":"208","author":"Fabbri","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic Expression of Sf3b1(K700E) Causes Impaired Erythropoiesis, Aberrant Splicing, and Sensitivity to Therapeutic Spliceosome Modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/leu.2016.251","article-title":"Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts","volume":"31","author":"Mupo","year":"2017","journal-title":"Leukemia"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1182\/blood-2011-08-373159","article-title":"Mutations of the SF3B1 splicing Factor in Chronic Lymphocytic Leukemia: Association with Progression and Fludarabine-Refractoriness","volume":"118","author":"Rossi","year":"2011","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1182\/blood-2012-05-429282","article-title":"The clinical significance of NOTCH1 and SF3B1 mutations in the UK LRF CLL4 trial","volume":"121","author":"Oscier","year":"2013","journal-title":"Blood"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1182\/blood-2014-01-546150","article-title":"Gene mutations and treatment outcome in chronic lymphocytic leukemia: Results from the CLL8 trial","volume":"123","author":"Stilgenbauer","year":"2014","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1016\/j.cell.2013.01.019","article-title":"Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia","volume":"152","author":"Landau","year":"2013","journal-title":"Cell"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1016\/j.ccell.2016.10.005","article-title":"Transcriptomic Characterization of SF3B1 Mutation Reveals Its Pleiotropic Effects in Chronic Lymphocytic Leukemia","volume":"30","author":"Wang","year":"2016","journal-title":"Cancer Cell"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/leu.2014.318","article-title":"The impact of SF3B1 mutations in CLL on the DNA-damage response","volume":"29","author":"Raa","year":"2015","journal-title":"Leukemia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: A randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1111\/j.1365-2141.2011.09000.x","article-title":"Chronic lymphocytic leukaemia with 17p deletion: A retrospective analysis of prognostic factors and therapy results","volume":"157","author":"Delgado","year":"2012","journal-title":"Br. J. Haematol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.3324\/haematol.2012.075325","article-title":"Spliceosome mutations exhibit specific associations with epigenetic modifiers and proto-oncogenes mutated in myelodysplastic syndrome","volume":"98","author":"Mian","year":"2013","journal-title":"Haematologica"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1182\/blood.V120.21.711.711","article-title":"SF3B1 Mutations in CLL Are Equivalent to p53\/ATM Dysfunction and Cause Defective Puma Upregulation in Response to Chemotherapy","volume":"120","author":"Derks","year":"2012","journal-title":"Blood"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1038\/leu.2013.263","article-title":"SF3B1 mutations correlated to cytogenetics and mutations in NOTCH1, FBXW7, MYD88, XPO1 and TP53 in 1160 untreated CLL patients","volume":"28","author":"Jeromin","year":"2014","journal-title":"Leukemia"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"176","DOI":"10.21037\/atm.2019.03.63","article-title":"SF3B1 mutation predicts unfavorable treatment-free survival in Chinese chronic lymphocytic leukemia patients","volume":"7","author":"Miao","year":"2019","journal-title":"Ann. Transl. Med."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/sj.leu.2404457","article-title":"ERIC recommendations on IGHV gene mutational status analysis in chronic lymphocytic leukemia","volume":"21","author":"Ghia","year":"2007","journal-title":"Leukemia"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"96","DOI":"10.7164\/antibiotics.50.96","article-title":"New Antitumor Substances, FR901463, FR901464 and FR901465. III. Structures of FR901463, FR901464 and FR901465","volume":"50","author":"Nakajima","year":"1997","journal-title":"J. Antibiot."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nchembio.2007.18","article-title":"Spliceostatin A targets SF3b and inhibits both splicing and nuclear retention of pre-mRNA","volume":"3","author":"Kaida","year":"2007","journal-title":"Nat. Chem. Biol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1021\/cb100356k","article-title":"Sudemycins, Novel Small Molecule Analogues of FR901464, Induce Alternative Gene Splicing","volume":"6","author":"Fan","year":"2011","journal-title":"ACS Chem. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1038\/nm.4493","article-title":"H3B-8800, an orally available small-molecule splicing modulator, induces lethality in spliceosome-mutant cancers","volume":"24","author":"Seiler","year":"2018","journal-title":"Nat. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"188","DOI":"10.7164\/antibiotics.57.188","article-title":"Pladienolides, new substances from culture of Streptomyces platensis Mer-11107. III. In vitro and in vivo antitumor activities","volume":"57","author":"Mizui","year":"2004","journal-title":"J. Antibiot."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Aptullahoglu, E., Ciardullo, C., Wallis, J.P., Marr, H., Marshall, S., Bown, N., Willmore, E., and Lunec, J. (2023). Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24032410"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1182\/blood-2016-10-692400","article-title":"Splicing factor gene mutations in hematologic malignancies","volume":"129","author":"Saez","year":"2017","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"609409","DOI":"10.3389\/fonc.2020.609409","article-title":"The Effect of SF3B1 Mutation on the DNA Damage Response and Nonsense-Mediated mRNA Decay in Cancer","volume":"10","author":"Leeksma","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/sj.leu.2402339","article-title":"CD38 expression is an important prognostic marker in chronic lymphocytic leukaemia","volume":"16","author":"Naschar","year":"2002","journal-title":"Leukemia"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1111\/bjh.18075","article-title":"Guideline for the treatment of chronic lymphocytic leukaemia","volume":"197","author":"Walewska","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"57","DOI":"10.2147\/OTT.S53876","article-title":"Uncovering the role of p53 splice variants in human malignancy: A clinical perspective","volume":"7","author":"Bourdon","year":"2013","journal-title":"OncoTargets Ther."},{"key":"ref_48","first-page":"609","article-title":"Short alternative splice transcripts of the mdm2 oncogene correlate to malignancy in human astrocytic neoplasms","volume":"58","author":"Matsumoto","year":"1998","journal-title":"Cancer Res."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1038\/sj.cdd.4400474","article-title":"Identification of two novel mRNA splice variants of bax","volume":"6","author":"Thomas","year":"1999","journal-title":"Cell Death Differ."},{"key":"ref_50","first-page":"1667","article-title":"Identification and characterization of two splicing variants of human Noxa","volume":"28","author":"Wang","year":"2008","journal-title":"Anticancer Res."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ccell.2018.12.013","article-title":"A Murine Model of Chronic Lymphocytic Leukemia Based on B Cell-Restricted Expression of Sf3b1 Mutation and Atm Deletion","volume":"35","author":"Yin","year":"2019","journal-title":"Cancer Cell"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/ng.1032","article-title":"Exome sequencing identifies recurrent mutations of the splicing factor SF3B1 gene in chronic lymphocytic leukemia","volume":"44","author":"Quesada","year":"2012","journal-title":"Nat. Genet."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1016\/j.csbj.2021.02.012","article-title":"Functional and conformational impact of cancer-associated SF3B1 mutations depends on the position and the charge of amino acid substitution","volume":"19","author":"Canbezdi","year":"2021","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1038\/leu.2014.331","article-title":"Disruption of SF3B1 results in deregulated expression and splicing of key genes and pathways in myelodysplastic syndrome hematopoietic stem and progenitor cells","volume":"29","author":"Dolatshad","year":"2015","journal-title":"Leukemia"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1007\/s11912-022-01274-4","article-title":"Richter\u2019s Transformation","volume":"24","author":"Sigmund","year":"2022","journal-title":"Curr. Oncol. Rep."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1038\/s41591-022-01927-8","article-title":"Detection of early seeding of Richter transformation in chronic lymphocytic leukemia","volume":"28","author":"Nadeu","year":"2022","journal-title":"Nat. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1182\/blood-2017-12-820910","article-title":"Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study","volume":"131","author":"Ahn","year":"2018","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/leu.2017.175","article-title":"Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL\/SLL","volume":"32","author":"Brown","year":"2018","journal-title":"Leukemia"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1182\/blood-2014-09-603670","article-title":"Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib","volume":"125","author":"Jain","year":"2015","journal-title":"Blood"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: A multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.14177","article-title":"NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome","volume":"175","author":"Eyre","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1111\/bjh.15508","article-title":"Use ofPD-1 (PDCD1) inhibitors for the treatment of Richter syndrome: Experience at a single academic centre","volume":"185","author":"Rogers","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"5446","DOI":"10.1182\/blood-2007-06-093906","article-title":"Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute\u2013Working Group 1996 guidelines","volume":"111","author":"Hallek","year":"2008","journal-title":"Blood"},{"key":"ref_65","first-page":"1167","article-title":"Quantification of CD38 expression in B-cell chronic lymphocytic leukemia (B-CLL): A comparison between antibody binding capacity (ABC) and relative median fluorescence (RMF)","volume":"45","author":"Dignum","year":"2004","journal-title":"Leuk. Lymphoma"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2141.2010.08425.x","article-title":"Mitoxantrone in combination with an inhibitor of DNA-dependent protein kinase: A potential therapy for high risk B-cell chronic lymphocytic leukaemia","volume":"152","author":"Elliott","year":"2011","journal-title":"Br. J. Haematol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11335\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:11:03Z","timestamp":1760127063000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/14\/11335"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,12]]},"references-count":66,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2023,7]]}},"alternative-id":["ijms241411335"],"URL":"https:\/\/doi.org\/10.3390\/ijms241411335","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,12]]}}}